Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.

One expert who studies emerging infectious diseases called Kennedy's past tweets and remarks about the HPV vaccine "complete ...

These beverages, packed with bioactive compounds, bring new hope in the fight against this disease, affecting thousands of ...

Robot uses a single port, or one “arm,” to help target tumors in the mouth, throat and nasal area that are typically found ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Screening and early detection, as well as the introduction of a human papillomavirus (HPV) vaccine, have fuelled transformative strides in decreasing the burden of cervical cancer for women and ...

The most common causes of head and neck cancer are excessive use of alcohol and tobacco. These account for around 75%. Pain in the shoulder can also be a symptom of lung cancer. Breast cancer may ...